Paul Gagnier

6.8k total citations · 1 hit paper
25 papers, 1.2k citations indexed

About

Paul Gagnier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Paul Gagnier has authored 25 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Paul Gagnier's work include Cancer Immunotherapy and Biomarkers (17 papers), Renal cell carcinoma treatment (7 papers) and CAR-T cell therapy research (5 papers). Paul Gagnier is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Renal cell carcinoma treatment (7 papers) and CAR-T cell therapy research (5 papers). Paul Gagnier collaborates with scholars based in United States, France and Canada. Paul Gagnier's co-authors include Howard I. Scher, Tomasz M. Beer, Kevin M. Chin, Susan F. Slovin, Andrea Harzstark, Celestia S. Higano, Joshi J. Alumkal, Omid Hamid, Sheela Tejwani and M. Brent McHenry and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Infectious Diseases.

In The Last Decade

Paul Gagnier

25 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

2013 436 citations Susan F. Slovin, Celestia S. Higano et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Gagnier United States	13	840	504	470	161	160	25	1.2k
A. Lavolé France	24	916 1.1×	897 1.8×	119 0.3×	135 0.8×	121 0.8×	105	1.7k
Patrizio Mazza Italy	22	680 0.8×	248 0.5×	205 0.4×	109 0.7×	54 0.3×	98	1.8k
C. Kortsik Germany	19	539 0.6×	712 1.4×	252 0.5×	258 1.6×	147 0.9×	59	1.4k
Aleksandr Lazaryan United States	21	797 0.9×	112 0.2×	443 0.9×	186 1.2×	45 0.3×	103	1.7k
Moshe Chaim Ornstein United States	21	723 0.9×	913 1.8×	198 0.4×	486 3.0×	36 0.2×	133	1.5k
V. Gounant France	23	831 1.0×	960 1.9×	92 0.2×	267 1.7×	84 0.5×	133	1.6k
Mi Kwon Spain	19	376 0.4×	101 0.2×	218 0.5×	158 1.0×	86 0.5×	113	1.1k
Carlos Gómez-Martín Spain	15	906 1.1×	406 0.8×	321 0.7×	274 1.7×	60 0.4×	46	1.6k
Andrew Gross United States	11	855 1.0×	114 0.2×	291 0.6×	77 0.5×	197 1.2×	30	1.3k
Karin Hohloch Germany	13	249 0.3×	123 0.2×	208 0.4×	117 0.7×	74 0.5×	40	960

Countries citing papers authored by Paul Gagnier

Since Specialization

Citations

This map shows the geographic impact of Paul Gagnier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Gagnier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Gagnier more than expected).

Fields of papers citing papers by Paul Gagnier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Gagnier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Gagnier. The network helps show where Paul Gagnier may publish in the future.

Co-authorship network of co-authors of Paul Gagnier

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Gagnier. A scholar is included among the top collaborators of Paul Gagnier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Gagnier. Paul Gagnier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hammers, Hans J., Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2016). Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study. Annals of Oncology. 27. vi364–vi364. 11 indexed citations

Abernethy, Amy Pickar, Michael A. Postow, Jason Chesney, et al.. (2015). Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase II study (CheckMate 069).. Journal of Clinical Oncology. 33(15_suppl). 9029–9029. 7 indexed citations

Hammers, Hans J., Elizabeth R. Plimack, Cora N. Sternberg, et al.. (2015). CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.. Journal of Clinical Oncology. 33(15_suppl). TPS4578–TPS4578. 37 indexed citations

Hammers, Hans J., Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2015). Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 33(15_suppl). 4516–4516. 55 indexed citations

Hodi, F. Stephen, Michael A. Postow, Jason Chesney, et al.. (2015). Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone. Cancer Research. 75(15_Supplement). 2860–2860. 1 indexed citations

Hodi, F. Stephen, Michael A. Postow, Jason Chesney, et al.. (2015). Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.. Journal of Clinical Oncology. 33(15_suppl). 9004–9004. 29 indexed citations

Hammers, Hans J., Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2014). Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 32(15_suppl). 4504–4504. 116 indexed citations

Amin, A., Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2014). Nivolumab (N) (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Sunitinib (S) or Pazopanib (P) in Patients (Pts) with Metastatic Renal Cell Carcinoma (Mrcc). Annals of Oncology. 25. iv362–iv362. 20 indexed citations

Amin, Asim, Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 32(15_suppl). 5010–5010. 201 indexed citations

10.

Slovin, Susan F., Celestia S. Higano, Omid Hamid, et al.. (2013). Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of Oncology. 24(7). 1813–1821. 436 indexed citations breakdown →

11.

Drake, Charles G., Howard I. Scher, Alberto Bossi, et al.. (2012). CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D).. Journal of Clinical Oncology. 30(15_suppl). TPS4689–TPS4689. 2 indexed citations

12.

Slovin, Susan F., Omid Hamid, Sheela Tejwani, et al.. (2012). Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. Journal of Clinical Oncology. 30(5_suppl). 25–25. 12 indexed citations

13.

Beer, Tomasz M., Christopher J. Logothetis, Padmanee Sharma, et al.. (2012). CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 30(15_suppl). TPS4691–TPS4691. 3 indexed citations

14.

Montorsi, Francesco, Claus G. Roehrborn, Michael Borre, et al.. (2011). The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4‐year data from the Combination of Avodart and Tamsulosin (CombAT) study. British Journal of Urology. 107(9). 1426–1431. 45 indexed citations

15.

Haillot, O., A Fraga, Pushkar' DIu, et al.. (2011). The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. Prostate Cancer and Prostatic Diseases. 14(4). 302–306. 9 indexed citations

16.

Sartor, Oliver, et al.. (2009). Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.. PubMed. 16(5). 4806–12. 14 indexed citations

17.

Gagnier, Paul, et al.. (2001). SAT0087 The effect of meloxicam versus usual care nsaids for the treatment of osteoarthritis in a ususal care setting. the results of the improve trial. Annals of the Rheumatic Diseases. 60. A183–A183. 1 indexed citations

18.

Mirochnick, Mark, Terry Fenton, Paul Gagnier, et al.. (1998). Pharmacokinetics of Nevirapine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates. The Journal of Infectious Diseases. 178(2). 368–374. 160 indexed citations

19.

Mirochnick, Mark, John L. Sullivan, Paul Gagnier, Terry Fenton, & Rhoda Sperling. (1997). SAFETY AND PHARMACOKINETICS (PK) OF NEVIRAPINE (NVP) IN NEONATES BORN TO HIV-1 INFECTED WOMEN. ♦ 744. Pediatric Research. 41. 126–126. 3 indexed citations

20.

Gagnier, Paul. (1993). Review of the Safety of Diclofenac/Misoprostol. Drugs. 45(Supplement 1). 31–35. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact